James E Flynn - Net Worth and Insider Trading

James E Flynn Net Worth

The estimated net worth of James E Flynn is at least $3.4 Billion dollars as of 2025-04-30. James E Flynn is the Director, 10% Owner of Nuvalent Inc and owns about 17,991,024 shares of Nuvalent Inc (NUVL) stock worth over $1.4 Billion. James E Flynn is the of AveXis Inc and owns about 2,236,700 shares of AveXis Inc (AVXS) stock worth over $487 Million. James E Flynn is also the 10% Owner of ARS Pharmaceuticals Inc and owns about 10,514,657 shares of ARS Pharmaceuticals Inc (SPRY) stock worth over $146 Million. Besides these, James E Flynn also holds Mirum Pharmaceuticals Inc (MIRM) , Shockwave Medical Inc (SWAV) , AdaptHealth Corp (AHCO) , Antares Pharma Inc (ATRS) , Revolution Medicines Inc (RVMD) , Audentes Therapeutics Inc (BOLD) , XenoPort Inc (XNPT) , Rhythm Pharmaceuticals Inc (RYTM) , Edgewise Therapeutics Inc (EWTX) , Alpine Immune Sciences Inc (ALPN) , Arena Pharmaceuticals Inc (ARNA) , Larimar Therapeutics Inc (LRMR) , Axogen Inc (AXGN) , Schrodinger Inc (SDGR) , NxStage Medical Inc (NXTM) , Kiniksa Pharmaceuticals International PLC (KNSA) , Avadel Pharmaceuticals PLC (AVDL) , Constellation Pharmaceuticals Inc (CNST) , Bicara Therapeutics Inc (BCAX) , Vanda Pharmaceuticals Inc (VNDA) , Rigel Pharmaceuticals Inc (RIGL) , Regenxbio Inc (RGNX) , Invuity Inc (IVTY) , Arvinas Inc (ARVN) , eHealth Inc (EHTH) , Xeris Biopharma Holdings Inc (XERS) , Catalyst Biosciences Inc (CBIO) , Terns Pharmaceuticals Inc (TERN) , Singular Genomics Systems Inc (OMIC) , SteadyMed Ltd (STDY) , CAS Medical Systems Inc (CASM) , Aclaris Therapeutics Inc (ACRS) , Nkarta Inc (NKTX) , Lumos Pharma Inc (LUMO) , Annexon Inc (ANNX) , Editas Medicine Inc (EDIT) , Alimera Sciences Inc (ALIM) , Societal CDMO Inc (SCTL) , Cabaletta Bio Inc (CABA) , Xilio Therapeutics Inc (XLO) , PepGen Inc (PEPG) , Black Diamond Therapeutics Inc (BDTX) , Proteon Therapeutics Inc (PRTO) , Neos Therapeutics Inc (NEOS) , CytomX Therapeutics Inc (CTMX) , CalciMedica Inc (CALC) , Generation Bio Co (GBIO) , Frequency Therapeutics Inc (FREQ) , Streamline Health Solutions Inc (STRM) , Oncorus Inc (ONCR) , Homology Medicines Inc (FIXX) , Acutus Medical Inc (AFIB) , Mallinckrodt PLC (MNKKQ) , Zafgen Inc (ZFGN) , aTyr Pharma Inc (ATYR) , Syros Pharmaceuticals Inc (SYRS) , Cyclacel Pharmaceuticals Inc (CYCC) , Dynavax Technologies Corp (DVAX) , The Medicines Co (MDCO) , Davis Select U.S. Equity ETF (DUSA) . Details can be seen in James E Flynn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James E Flynn has not made any transactions after 2024-11-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of James E Flynn

To

James E Flynn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James E Flynn owns 85 companies in total, including Oncorus Inc (ONCR) , Larimar Therapeutics Inc (LRMR) , and CalciMedica Inc (CALC) among others .

Click here to see the complete history of James E Flynn’s form 4 insider trades.

Insider Ownership Summary of James E Flynn

Ticker Company Transaction Date Type of Owner
ONCR Oncorus Inc 2022-12-30 director & 10 percent owner & other: *Possible Member of 10% Group
LRMR Larimar Therapeutics Inc 2024-02-16 10 percent owner & other: Possible Member of 10% Group
CALC CalciMedica Inc 2020-09-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2021-07-19 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-07-28 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-07-21 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-07-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-06-16 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2021-01-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-03-13 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2020-02-18 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-10 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-03 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-01-30 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2019-11-08 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2019-10-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-10-07 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-06-06 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-06-27 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-03-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-02-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-10-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-07-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-07-23 10 percent owner & other: Possible member of 10% group
LIMIT LIMIT 2018-06-25 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2014-10-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-05-29 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2018-05-09 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2018-03-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-10-10 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-06-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-04-27 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2017-01-26 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-12-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-09-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-06-23 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-25 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-07-06 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-19 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-17 director & 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2016-02-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-12-17 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-12-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-10-14 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-09-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-09-22 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-07-28 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-05-12 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-03-25 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2015-02-11 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-11-21 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-08-06 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2014-07-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2014-04-22 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2012-12-04 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2011-05-26 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2011-04-06 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2008-10-27 10 percent owner
LIMIT LIMIT 2010-08-16 10 percent owner & other: Possible Members of 10% Group
LIMIT LIMIT 2009-07-13 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2008-03-11 10 percent owner
LIMIT LIMIT 2008-10-22 10 percent owner
LIMIT LIMIT 2007-11-05 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2007-10-19 10 percent owner
LIMIT LIMIT 2021-03-30 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2024-03-12 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2021-04-29 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-03-10 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2020-07-16 director & 10 percent owner & other: *Director by Deputization
LIMIT LIMIT 2021-02-09 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-05-10 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2021-10-26 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2021-06-01 10 percent owner & other: *Possible Member of 10% Group
LIMIT LIMIT 2024-10-22 director & 10 percent owner & other: Director by Deputization
LIMIT LIMIT 2021-07-27 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2018-05-08 10 percent owner & other: *Possible member of 10% group
LIMIT LIMIT 2022-11-08 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2020-02-01 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2022-11-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2024-11-12 director & 10 percent owner & other: Director by deputization
LIMIT LIMIT 2022-11-08 10 percent owner & other: Possible Member of 10% Group
LIMIT LIMIT 2019-10-02 10 percent owner & other: Possible Member of 10% Group

James E Flynn Latest Holdings Summary

James E Flynn currently owns a total of 63 stocks. Among these stocks, James E Flynn owns 17,991,024 shares of Nuvalent Inc (NUVL) as of October 22, 2024, with a value of $1.4 Billion and a weighting of 40.24%. James E Flynn owns 2,236,700 shares of AveXis Inc (AVXS) as of February 17, 2016, with a value of $487 Million and a weighting of 14.36%. James E Flynn also owns 10,514,657 shares of ARS Pharmaceuticals Inc (SPRY) as of November 12, 2024, with a value of $146 Million and a weighting of 4.31%. The other 60 stocks Mirum Pharmaceuticals Inc (MIRM) , Shockwave Medical Inc (SWAV) , AdaptHealth Corp (AHCO) , Antares Pharma Inc (ATRS) , Revolution Medicines Inc (RVMD) , Audentes Therapeutics Inc (BOLD) , XenoPort Inc (XNPT) , Rhythm Pharmaceuticals Inc (RYTM) , Edgewise Therapeutics Inc (EWTX) , Alpine Immune Sciences Inc (ALPN) , Arena Pharmaceuticals Inc (ARNA) , Larimar Therapeutics Inc (LRMR) , Axogen Inc (AXGN) , Schrodinger Inc (SDGR) , NxStage Medical Inc (NXTM) , Kiniksa Pharmaceuticals International PLC (KNSA) , Avadel Pharmaceuticals PLC (AVDL) , Constellation Pharmaceuticals Inc (CNST) , Bicara Therapeutics Inc (BCAX) , Vanda Pharmaceuticals Inc (VNDA) , Rigel Pharmaceuticals Inc (RIGL) , Regenxbio Inc (RGNX) , Invuity Inc (IVTY) , Arvinas Inc (ARVN) , eHealth Inc (EHTH) , Xeris Biopharma Holdings Inc (XERS) , Catalyst Biosciences Inc (CBIO) , Terns Pharmaceuticals Inc (TERN) , Singular Genomics Systems Inc (OMIC) , SteadyMed Ltd (STDY) , CAS Medical Systems Inc (CASM) , Aclaris Therapeutics Inc (ACRS) , Nkarta Inc (NKTX) , Lumos Pharma Inc (LUMO) , Annexon Inc (ANNX) , Editas Medicine Inc (EDIT) , Alimera Sciences Inc (ALIM) , Societal CDMO Inc (SCTL) , Cabaletta Bio Inc (CABA) , Xilio Therapeutics Inc (XLO) , PepGen Inc (PEPG) , Black Diamond Therapeutics Inc (BDTX) , Proteon Therapeutics Inc (PRTO) , Neos Therapeutics Inc (NEOS) , CytomX Therapeutics Inc (CTMX) , CalciMedica Inc (CALC) , Generation Bio Co (GBIO) , Frequency Therapeutics Inc (FREQ) , Streamline Health Solutions Inc (STRM) , Oncorus Inc (ONCR) , Homology Medicines Inc (FIXX) , Acutus Medical Inc (AFIB) , Mallinckrodt PLC (MNKKQ) , Zafgen Inc (ZFGN) , aTyr Pharma Inc (ATYR) , Syros Pharmaceuticals Inc (SYRS) , Cyclacel Pharmaceuticals Inc (CYCC) , Dynavax Technologies Corp (DVAX) , The Medicines Co (MDCO) , Davis Select U.S. Equity ETF (DUSA) have a combined weighting of 41.08% among all his current holdings.

Latest Holdings of James E Flynn

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NUVL Nuvalent Inc 2024-10-22 17,991,024 75.87 1,364,978,991
AVXS AveXis Inc 2016-02-17 2,236,700 217.83 487,220,361
SPRY ARS Pharmaceuticals Inc 2024-11-12 10,514,657 13.92 146,364,025
MIRM Mirum Pharmaceuticals Inc 2022-06-06 3,244,434 42.54 138,018,222
SWAV Shockwave Medical Inc 2019-03-11 342,146 334.75 114,533,374
AHCO AdaptHealth Corp 2024-03-12 13,257,940 8.37 110,968,958
ATRS Antares Pharma Inc 2015-09-30 15,451,126 5.59 86,371,794
RVMD Revolution Medicines Inc 2020-02-18 2,096,384 40.67 85,259,937
BOLD Audentes Therapeutics Inc 2016-07-25 1,403,654 59.97 84,177,130
XNPT XenoPort Inc 2016-02-19 11,572,125 7.07 81,814,924
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 937,010 65.22 61,111,792
EWTX Edgewise Therapeutics Inc 2021-03-30 3,933,137 15.46 60,806,298
ALPN Alpine Immune Sciences Inc 2015-06-23 933,103 64.97 60,623,702
ARNA Arena Pharmaceuticals Inc 2007-10-15 512,564 99.99 51,251,274
LRMR Larimar Therapeutics Inc 2024-02-16 21,231,974 2.39 50,744,418
AXGN Axogen Inc 2016-07-21 3,000,000 16.51 49,530,000
SDGR Schrodinger Inc 2020-02-10 1,596,167 25.78 41,149,185
NXTM NxStage Medical Inc 2009-12-15 1,292,874 30.00 38,786,220
KNSA Kiniksa Pharmaceuticals International PLC 2018-05-29 1,226,890 25.88 31,751,913
AVDL Avadel Pharmaceuticals PLC 2018-06-25 3,674,506 8.61 31,637,497
CNST Constellation Pharmaceuticals Inc 2018-07-23 835,843 33.99 28,410,304
BCAX Bicara Therapeutics Inc 2024-09-17 1,795,174 14.88 26,712,189
VNDA Vanda Pharmaceuticals Inc 2016-09-23 4,328,344 4.43 19,174,564
RIGL Rigel Pharmaceuticals Inc 2011-05-26 674,229 19.57 13,194,662
RGNX Regenxbio Inc 2015-09-22 1,344,042 9.41 12,647,435
IVTY Invuity Inc 2016-12-14 1,690,498 7.39 12,492,780
ARVN Arvinas Inc 2018-10-01 1,233,734 9.37 11,560,088
EHTH eHealth Inc 2017-04-27 1,831,554 5.86 10,732,906
XERS Xeris Biopharma Holdings Inc 2019-02-11 2,355,136 4.41 10,386,150
CBIO Catalyst Biosciences Inc 2018-03-08 1,113,222 7.67 8,537,856
TERN Terns Pharmaceuticals Inc 2021-02-09 2,382,033 3.11 7,408,123
OMIC Singular Genomics Systems Inc 2021-06-01 303,734 20.01 6,077,717
STDY SteadyMed Ltd 2015-03-25 1,267,733 4.73 5,990,038
CASM CAS Medical Systems Inc 2017-01-26 2,358,636 2.45 5,778,658
ACRS Aclaris Therapeutics Inc 2019-06-27 4,123,266 1.33 5,483,944
NKTX Nkarta Inc 2020-07-14 2,419,872 1.95 4,718,750
LUMO Lumos Pharma Inc 2021-01-08 784,568 4.34 3,405,025
ANNX Annexon Inc 2020-07-28 1,617,828 1.90 3,073,873
EDIT Editas Medicine Inc 2016-02-08 1,809,400 1.55 2,804,570
ALIM Alimera Sciences Inc 2015-12-08 391,870 5.54 2,170,960
SCTL Societal CDMO Inc 2017-06-14 1,901,685 1.10 2,091,854
CABA Cabaletta Bio Inc 2019-10-29 1,628,506 1.28 2,084,488
XLO Xilio Therapeutics Inc 2021-10-26 2,287,944 0.76 1,729,457
PEPG PepGen Inc 2022-05-10 953,626 1.53 1,459,048
BDTX Black Diamond Therapeutics Inc 2020-02-03 778,790 1.60 1,246,064
PRTO Proteon Therapeutics Inc 2017-11-30 30,622 33.41 1,023,081
NEOS Neos Therapeutics Inc 2015-07-28 858,332 1.15 987,082
CTMX CytomX Therapeutics Inc 2015-10-14 946,024 0.65 616,429
CALC CalciMedica Inc 2020-09-29 377,265 1.52 573,443
GBIO Generation Bio Co 2020-06-16 1,186,215 0.42 501,057
FREQ Frequency Therapeutics Inc 2019-10-07 1,231,434 0.30 368,938
STRM Streamline Health Solutions Inc 2015-12-17 125,033 2.93 366,597
ONCR Oncorus Inc 2022-12-30 2,597,314 0.13 327,262
FIXX Homology Medicines Inc 2020-01-30 227,073 0.93 212,245
AFIB Acutus Medical Inc 2021-07-19 5,415,449 0.03 166,796
MNKKQ Mallinckrodt PLC 2018-05-09 8,308,455 0.02 166,169
ZFGN Zafgen Inc 2016-07-20 142,841 0.99 141,413
ATYR aTyr Pharma Inc 2015-05-12 36,538 3.38 123,498
SYRS Syros Pharmaceuticals Inc 2016-07-06 209,522 0.03 6,286
CYCC Cyclacel Pharmaceuticals Inc 2008-03-11 84 0.30 26
DVAX Dynavax Technologies Corp 2008-10-22 0 11.55 0
MDCO The Medicines Co 2011-04-06 0 84.90 0
DUSA Davis Select U.S. Equity ETF 2011-03-22 0 42.09 0

Holding Weightings of James E Flynn


James E Flynn Form 4 Trading Tracker

According to the SEC Form 4 filings, James E Flynn has made a total of 2 transactions in Nuvalent Inc (NUVL) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Nuvalent Inc is the sale of 2,000,000 shares on October 22, 2024, which brought James E Flynn around $196 Million.

According to the SEC Form 4 filings, James E Flynn has made a total of 0 transactions in AveXis Inc (AVXS) over the past 5 years. The most-recent trade in AveXis Inc is the acquisition of 750,317 shares on February 17, 2016, which cost James E Flynn around $15 Million.

According to the SEC Form 4 filings, James E Flynn has made a total of 1 transactions in ARS Pharmaceuticals Inc (SPRY) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in ARS Pharmaceuticals Inc is the sale of 563,270 shares on November 12, 2024, which brought James E Flynn around $10 Million.

More details on James E Flynn's insider transactions can be found in the Insider Trading History of James E Flynn table.

Insider Trading History of James E Flynn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James E Flynn Trading Performance

GuruFocus tracks the stock performance after each of James E Flynn's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James E Flynn is -0.79%. GuruFocus also compares James E Flynn's trading performance to market benchmark return within the same time period. The performance of stocks bought by James E Flynn within 3 months outperforms 20 times out of 70 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James E Flynn's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James E Flynn

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
25 out of 66 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.57 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 0.9 LIMIT LIMIT LIMIT LIMIT LIMIT

James E Flynn Ownership Network

Ownership Network List of James E Flynn

No Data

Ownership Network Relation of James E Flynn

Insider Network Chart

James E Flynn Owned Company Details

What does Oncorus Inc do?

Who are the key executives at Oncorus Inc?

James E Flynn is the director & 10 percent owner & other: *Possible Member of 10% Group of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and CFO and Treasurer Rick Wanstall .

Oncorus Inc (ONCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oncorus Inc Insider Transactions

No Available Data

James E Flynn Mailing Address

Above is the net worth, insider trading, and ownership report for James E Flynn. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, James E Flynn's mailing address is: New York Ny 10017.